ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer
The ReDiscover-2 trial is currently enrolling patients with PIK3CA-mutated advanced breast cancer who have progressed after CDK4/6 inhibitor therapy. Dr. Sarah Sammons and Dr. Charles Turck review findings from the ReDiscover trial supporting the initiation of ReDiscover-2, and…